PMWC 2026: Beyond the Read

Structural variants (SVs) underlie many of the diseases genomics research focuses on most, yet they remain far harder to detect and interpret than single-nucleotide variants, leaving a meaningful share of rare disease research without a clear genetic answer. At the Precision Medicine World Conference (PMWC) 2026, a panel of genomics leaders examined what it will take to move long-read sequencing and electronic genome mapping (EGM) from parallel research tracks into an integrated, accessible SV pipeline.

In a moderated panel discussion, Nabsys founder and CEO Barrett Bready, M.D., joined genomics leaders from Oxford Nanopore, Stanford University, and Galatea Bio to compare perspectives from genome mapping, sequencing technology, and oncology. Their shared conclusion: no single platform solves SV detection alone, but pairing low-cost short-read sequencing with high-resolution, cost-effective tools such as EGM can bring genome-wide SV resolution within reach of routine research workflows.

Explore how Nabsys and other genomics leaders are integrating long-read data to advance SV research in this PMWC 2026 panel recording.